Home / Stocks / Laurus Labs Limited
LAURUSLABS

Laurus Labs Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,306.0

Change

-16.5 (-0.71%)

Open

₹2,322.5

Prev. Close

₹2,322.5

Day High

₹2,328.9

Day Low

₹2,272.6

Volume Analysis

Traded

1,895,387

Delivered

1,045,979

Delivery %

55.19%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (30.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,388.7 ₹2,358.8 ₹2,332.4 ₹2,302.5 ₹2,276.1 ₹2,246.2 ₹2,219.8
Fibonacci ₹2,358.8 ₹2,337.29 ₹2,324.01 ₹2,302.5 ₹2,280.99 ₹2,267.71 ₹2,246.2
Camarilla ₹2,321.48 ₹2,316.32 ₹2,311.16 ₹2,302.5 ₹2,300.84 ₹2,295.68 ₹2,290.52

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+107.67%

1 Week

-3.92%

1 Month

+14.58%

3 Months

+27.97%

6 Months

+71.64%

1 Year

+133.61%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹203.66

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

19.09%

Net margin 17.03% × asset turnover 0.59x × equity multiplier 1.9x

Company Overview

Sector

Healthcare

Market Cap

₹125,380 Cr

P/E (TTM)

93.6

ROE

18.3%

Book Value

₹112.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Laurus Labs Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (92/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%). FII holding has been rising.

TopFund Score — Fundamentals Quality

64/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

92

Growth

19

Valuation

0

Cash Flow

62

Corporate Governance

55

Momentum

89

Institutional Ownership

83

Business Quality

85

Risk & Volatility

89

Liquidity

85

From Screener.in

  • +Company has been maintaining a healthy dividend payout of 19.0%
  • −Stock is trading at 20.7 times its book value
  • −The company has delivered a poor sales growth of 7.19% over past five years.
  • −Company has a low return on equity of 10.4% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,224 1,195 1,440 1,195 1,224 1,415 1,720 1,570 1,653 1,778 1,812 2,026 2,206
Expenses + 1,037 1,014 1,198 1,024 1,045 1,130 1,300 1,187 1,250 1,298 1,299 1,388 1,456
Operating Profit 188 181 241 171 178 285 421 382 403 480 512 638 750
OPM % 15.0% 15.0% 17.0% 14.0% 15.0% 20.0% 24.0% 24.0% 24.0% 27.0% 28.0% 32.0% 34.0%
Other Income + 2 2 19 3 5 9 59 10 27 6 12 9 13
Interest 42 51 50 49 53 58 56 52 40 39 40 42 44
Depreciation 93 98 102 106 108 106 110 117 120 121 122 124 127
Profit before tax 54 35 107 18 23 131 312 224 270 327 361 481 592
Tax % 27.0% 27.0% 30.0% 34.0% 22.0% 31.0% 25.0% 28.0% 28.0% 22.0% 22.0% 25.0% 26.0%
Net Profit + 37 23 75 13 20 93 233 162 194 252 282 362 436
EPS in Rs 1 0 1 0 0 2 4 3 4 5 5 7 8
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -22 -23 4 1 0 18 19 31 35 26 5 29 33

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,327 1,778 1,905 2,056 2,292 2,832 4,814 4,936 6,041 5,041 5,554 6,813 7,823
Expenses + 1,126 1,415 1,497 1,642 1,935 2,266 3,262 3,512 4,448 4,261 4,499 5,028 5,442
Operating Profit 200 362 408 414 357 565 1,552 1,424 1,592 779 1,055 1,785 2,381
OPM % 15.0% 20.0% 21.0% 20.0% 16.0% 20.0% 32.0% 29.0% 26.0% 15.0% 19.0% 26.0% 30.0%
Other Income + 34 4 32 29 15 5 23 14 6 24 75 47 40
Interest 106 111 100 80 88 90 68 102 165 183 216 171 166
Depreciation 62 86 106 125 164 187 205 251 324 385 430 480 494
Profit before tax 67 169 234 237 120 294 1,301 1,084 1,109 236 484 1,182 1,761
Tax % -2.0% 21.0% 19.0% 29.0% 22.0% 13.0% 24.0% 23.0% 28.0% 29.0% 27.0% 25.0% —
Net Profit + 68 134 190 168 94 255 984 832 793 162 358 890 1,332
EPS in Rs 1 3 4 3 2 5 18 15 15 3 7 16 25
Dividend Payout % 0.0% 2.0% 8.0% 9.0% 17.0% 10.0% 11.0% 13.0% 14.0% 27.0% 18.0% 12.0% —
Sales growth 14 34 7 8 11 24 70 3 22 -17 10 23 23

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 640 774 1,225 1,377 1,452 1,663 2,490 3,244 3,930 4,003 4,365 5,192 5,953
Borrowings + 888 1,094 842 980 1,036 1,079 1,482 1,777 2,015 2,577 2,764 2,518 2,625
Other Liabilities + 345 339 481 554 737 901 1,671 1,840 1,608 1,699 2,099 2,693 2,828
Total Liabilities 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,387 9,336 10,511 11,514
Fixed Assets + 801 1,021 1,230 1,481 1,629 1,726 2,171 2,652 3,409 3,890 4,123 4,371 4,351
CWIP 110 70 143 163 110 67 362 813 551 423 458 773 1,282
Investments 7 7 3 3 3 3 3 31 50 124 233 309 310
Other Assets + 970 1,126 1,277 1,369 1,589 1,953 3,214 3,472 3,651 3,950 4,521 5,058 5,570
Total Assets 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,387 9,336 10,511 11,514
Equity Capital 16 16 106 106 106 107 107 107 108 108 108 108 108

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -65 182 332 342 298 347 733 911 994 666 602 1,624
Cash from Investing Activity + -397 -312 -289 -384 -253 -221 -941 -914 -997 -822 -680 -1,086
Cash from Financing Activity + 486 103 -54 42 -45 -128 255 30 -27 250 39 -525
Net Cash Flow 24 -27 -10 1 0 -1 47 27 -30 93 -39 13
Free Cash Flow -447 -144 55 -49 44 125 49 34 6 -10 61 560
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -24 59 94 98 91 68 62 77 80 99 70 107

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 27.18% → 27.47%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 36.3% 35.07% 33.59% 33.69% 34.09% 35.09% 34.78% 34.52% 33.57% 32.73% 30.79% 29.85%
Promoters 27.18% 27.18% 27.18% 27.18% 27.62% 27.62% 27.6% 27.6% 27.49% 27.49% 27.47% 27.47%
FII 25.39% 25.98% 25.67% 26.08% 25.56% 25.51% 25.7% 26.17% 26.52% 25.82% 28.0% 30.84%
DII 11.13% 11.78% 13.56% 13.05% 12.74% 11.78% 11.94% 11.72% 12.42% 13.96% 13.73% 11.86%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Laurus Labs Limited (this stock) 125,380 93.6 20.73 18.3%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%
Dr. Reddy S Laboratories 115,092 41.1 2.96 11.2%
Cipla Ltd 112,563 36.2 3.18 11.6%
Mankind Pharma Limited 108,424 46.5 6.16 13.1%
Aurobindo Pharma Ltd 104,215 25.7 2.64 10.1%

Which Mutual Funds Hold Laurus Labs Limited?

Frequently Asked Questions about Laurus Labs Limited

Community Sentiment

What are other investors saying about Laurus Labs Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.